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Mitochondrial DNA
YeastWe have created and analyzed the properties of a yeast model of the human mitochondrial DNA T8993C
mutation that has been associated with maternally-inherited Leigh syndrome and/or with neurogenic
muscle weakness, ataxia and retinitis pigmentosa. This mutation changes a highly conserved leucine to
proline in the Atp6p subunit of the ATP synthase, at position 156 in the human protein, position 183 in yeast.
In vitro the yeast T8993C mitochondria showed a 40–50% decrease in the rate of ATP synthesis. The ATP-
driven translocation of protons across the inner mitochondrial membrane was normal in the mutant and
fully sensitive to oligomycin, an inhibitor of the ATP synthase proton channel. However under conditions of
maximal ATP hydrolytic activity, using non-osmotically protected mitochondria, the mutant ATPase activity
was poorly inhibited by oligomycin (by 40% versus 85% in wild type cells). These anomalies were attributed
by BN-PAGE and mitochondrial protein synthesis analyses to a less efﬁcient incorporation of Atp6p within
the ATP synthase. Interestingly, the cytochrome c oxidase content was selectively decreased by 40–50% in
T8993C yeast, apparently due to a reduced synthesis of its mitochondrially encoded Cox1p subunit. This
observation further supports the existence of a control of cytochrome c oxidase expression by the ATP
synthase in yeast mitochondria. Despite the ATPase deﬁciency, growth of the atp6-L183P mutant on
respiratory substrates and the efﬁciency of oxidative phosphorylation were similar to that of wild type,
indicating that the mutation did not affect the proton permeability of the mitochondrial inner membrane.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Most of the ATP in human cells is produced by an F1F0-type ATP
synthase or complex V located in the inner mitochondrial membrane
[1]. This enzyme utilizes the energy of the electrochemical proton
gradient established by the mitochondrial electron transport chain to
drive the synthesis of ATP from ADP and inorganic phosphate. Hence
it is not surprising that pronounced defects in the ATP synthase can
be responsible for very deleterious disorders in humans, especially in
the highly energy-demanding neuromuscular system [2–4]. Such
disorders like NARP (neuropathy ataxia retinitis pigmentosa) and
MILS (maternally-inherited Leigh's syndrome) have been associated
to several mutations in the mitochondrial ATP6 gene encoding the
Atp6p subunit of the ATP synthase. This subunit is essential for the
ATP synthase proton translocating activity by providing a pathway for
protons across the inner mitochondrial membrane [5].: +33 5 56 99 90 51.
di Rago).
olumbia University, New York,
ll rights reserved.One of the known pathogenic ATP6mutations, T8993C, leads to the
replacement of a highly conserved leucine to proline at amino acid
position 156 of human Atp6p [6,7]. Although unequivocal genetic
evidence for the pathogenicity of this mutation has been provided, the
underlying disease mechanism is still poorly understood. Furthermore,
there is no clear evidence that T8993C signiﬁcantly compromises the
production of ATP, especially in cultured cells (ﬁbroblasts, cybrids)
where onlyamodest, if any, deﬁcit in cellular energy provision has been
observed, even in cells that are homoplasmic for thismutation [4,8–10].
However, a recent study of fresh muscle biopsies from patients with a
95% T8993C load revealed a substantial decrease (50%) of ATP synthesis
that was apparently at least in part due to defects in the assembly/
stability of the ATP synthase [11]. Whether special features related to
the type of sample analyzed (cultured cells or patients' tissues) are
responsible for the observed variations in ATP synthesis is not known.
To better appreciate the consequences of T8993C on the ATP
synthase, we have created and analyzed a yeast model of this
mutation. The yeast and human ATP synthases are very similar, not
only in their structure but also in their assembly pathway [12,13]. The
Atp6p region modiﬁed by T8993C, a transmembrane segment
presumed to carry many of the residues involved in proton
translocation, is highly similar in both species [3,4]. Speciﬁc structural
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the ATP synthase in yeast and humans. This was indeed observed
recently in a study aiming to model the NARP/MILS T8993G mutation
into yeast that converts the leucine 156 of Atp6p into arginine [14]. As
in humans [8,15–21], this mutation resulted in a strong ATP
production deﬁcit (90%) in yeast that was apparently due to a local
disruption within the enzyme proton channel. We show here that the
T8993C mutation in yeast has, like in humans, less dramatic
consequences on the ATP synthase. However, there was a substantial
deﬁcit of ATP synthesis of about 50% that was apparently in large part
due to a less efﬁcient incorporation of Atp6p within the ATP synthase.
Interestingly, as a secondary consequence of this is that the yeast
T8993C mutant showed a reduced content of the last complex of the
electron transport chain (cytochrome c oxidase or complex IV).
2. Experimental procedures
2.1. Yeast strains and media
The Saccharomyces cerevisiae strains and their genotypes are listed
in Table 1. The media used for growth of yeast were: YPGA (1% (w/v)
yeast extract, 1% (w/v) peptone, 2% (w/v) glucose and 40 mg l−1
adenine); N3 (1% (w/v) yeast extract, 1% (w/v) peptone, 2% (w/v)
glycerol and 50 mM potassium phosphate buffer pH 6.2); YPGALA (1%
(w/v) yeast extract, 1% (w/v) peptone, 2% (w/v) galactose and 40 mg
l−1 adenine); W0 (0.17% (w/v) yeast nitrogen base without amino
acids or ammonium sulfate, 0.5% (w/v) ammonium sulfate, 2% (w/v)
glucose, and other supplements depending on the strain auxotrophic
markers. Solid media contained 2% (w/v) agar.
2.2. Construction of atp6-L183P mutant strain RKY20
Using the QuikChange XL Site-directed Mutagenesis Kit from
Stratagene, the TTA codon 183 of the yeast ATP6 gene was changed
into the proline CCA codon with the primers 5′-GCTAGAGCTATTTCA-
CCAGGTTTAAGATTAGG and 5′-CCTAATCTTAAACCTGGTGAAA-
TAGTCTAGC (the mutagenic bases are in bold). The mutagenesis
was performed on a BamHI–EcoRI fragment of the ATP6 locus cloned
in pUC19 (plasmid pSDC8, see [22]). This fragment contains the ﬁrst
232 codons of ATP6. The mutated ATP6 fragment was cut out and
ligated with vector pJM2 cut with BamHI and EcoRI, to create vector
pRK4. The pJM2 plasmid contains the yeast mitochondrial COX2 gene
as a marker for mitochondrial transformation [23]. The 3′ part of the
wild type ATP6 locus was cut from plasmid pSDC9 by a SapI+EcoRI
digestion [14] and cloned via the same sites of pRK4, to give pRK5,
thus reconstructing a complete ATP6 gene containing the L183P
mutation in pJM2. The pRK5 plasmid was introduced by co-
transformation with the nuclear selectable LEU2 plasmid pFL46 into
the ρ0 strain DFS160 bymicroprojectile bombardment using a biolistic
PDS-1000/He particle delivery system (Bio-Rad) as described [24].
Mitochondrial transformants were identiﬁed among the Leu+ clones
by their ability to produce respiring clones when mated with the non-
respiring NB40-3C strain, which bears a deletion in the mitochondrial
COX2 gene. One mitochondrial transformant (synthetic ρ− RKY12)
was crossed to the atp6::ARG8m deletion strain MR10 [25]. The crossTable 1
Genotypes and sources of yeast strains.
Strain Nuclear genotype
DFS160 MATα leu2Δ ura3-52 ade2-101 arg8::URA3 kar1-1
NB40-3C MATa lys2 leu2-3,112 ura3-52 his3ΔHinDIII arg8::hisG
MR6 MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 ar
MR10 MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 ar
RKY12 MATα leu2Δ ura3-52 ade2-101 arg8::URA3 kar1-1
RKY20 MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 ar
MR14 MATa ade2-1 his3-11,15 trp1-1 leu2-3,112 ura3-1 CAN1 arbetween RKY12 and MR10 produced cytoductants (called RKY20)
harboring the MR10 nucleus and in which the ARG8m ORF had been
replaced with the atp6-L183R gene. The RKY20 clones were identiﬁed
by virtue of their ability to grow on glycerol and their inability to grow
in the absence of an external source of arginine. Sequencing of the
mutated atp6 locus in RKY20 revealed no changes other than L183P.
2.3. Miscellaneous procedures
Cells that were ρ+ in RKY20 cultures were identiﬁed by virtue of
their ability to form pink colonies in the presence of a limiting
amount of adenine, while ρ−/ρ0 cells gave white colonies, as
described [14]. For mitochondrial enzyme assays and membrane
potential analyses, mitochondria were prepared by the enzymatic
method [26] from MR6 and RKY20 strains grown to middle
exponential phase (3–4×107 cells ml−1) in YPGALA medium. Protein
amounts were determined by the procedure described in [27] in the
presence of 5% SDS. Oxygen consumption rates were measured with a
Clark electrode in the respiration buffer (0.65 M mannitol, 0.36 mM
EGTA, 5 mM Tris–phosphate, 10 mM Tris–maleate, pH 6.8) as
described [28]. For ATP synthesis rate measurements, mitochondria
(0.3 mg) were placed in a 2-ml thermostatically controlled chamber
at 28 °C in respiration buffer. The reaction was started by the addition
of 4 mM NADH and 1 mM ADP and stopped with 3.5% perchloric acid,
12.5 mM EDTA. Samples were then neutralized to pH 6.5 by addition
of 2 M KOH/0.3 M MOPS. The ATP was quantiﬁed by the luciferin/
luciferase assay (ThermoLabsystems) on an LKB bioluminometer. The
speciﬁc ATPase activity was measured at pH 8.4 as described in [29].
Variations in transmembrane potential (ΔΨ) were evaluated in the
respiration buffer by measurement of rhodamine 123 ﬂuorescence
quenching with a SAFAS Monaco ﬂuorescence spectrophotometer
[30]. Cytochrome spectral analysis was performed as in [31]. SDS-
PAGE was according to Laemmli [32]. Western blot analyses were
performed as described previously [33]. Polyclonal antibodies raised
against Atp6p, Atp7p, Atp1p, and Atp9p (a gift from J. Velours) were
used after 1:10000 dilution. Polyclonal antibodies against yeast
complex III subunit cytochrome b (a gift from T. Langer) were used
after 1:2000 dilution. Monoclonal antibodies against the Cox2p
subunit of complex IV (from Molecular Probes) were used after
1:5000 dilution. Nitrocellulose membranes were incubated with
peroxidase-labeled antibodies at a 1:10,000 dilution and revealed
with the ECL reagent of Amersham International. Pulse labeling of
mtDNA encoded proteins were performed as described in [25].
Quantiﬁcation of COX1 mRNA level was performed by real-time
PCR. For this, total yeast cellular RNA was prepared with the RNeasy
Mini Kit (Qiagen, Germany) and reverse transcribed using the
QuantiTect Reverse Transcription Kit (Qiagen, Germany) according
to the manufacturer's recommendations. The primers 5`GTGGTATGG-
CAGGAACAGC and 5`CTCCAATTAAAGCAGGCATTACT were used for
ampliﬁcation of COX1 cDNA. qPCR ampliﬁcation was performed using
LightCycler 1.5 and LightCycler FastStart DNA Master SYBR Green I
(Roche, Mannheim, Germany). The Pfafﬂ model [34] and the relative
expression software tool (REST-384&copy [35]) were used to estimate
COX1 mRNA level. Data normalization was carried out against the
transcript of the gene for nuclear 35S RNA as described in [36].mtDNA Source
ρ0 [23]
ρ+ cox2-62 [23]
g8::HIS3 ρ+ wt [25]
g8::HIS3 ρ+ atp6::ARG8m [25]
ρ− atp6-L183P This study
g8::HIS3 ρ+ atp6-L183P This study
g8::HIS3 ρ+ atp6-L183R [14]
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3.1. Genetic stability and respiratory growth of yeast mutant atp6-L183P
The leucine residue 156 of human Atp6p that is changed into
proline by the T8993C mutation corresponds to the leucine residue
183 of yeast Atp6p [3]. We converted the TTA triplet encoding this
residue into the CCA codon for proline (see Experimental procedures).
In view of earlier ﬁndings that mutations of the ATP synthase often
promote instability of the mitochondrial genome in the form of ρ−
clones issued from large deletions in the mtDNA [37], two indepen-
dent atp6-L183P clones (RKY20) were tested for the percentage of ρ−
cells in cultures grown under non-selective conditions in rich glucose
medium. The two cultures contained less than 5% secondary ρ− cells
indicating that the leucine to proline change did not adversely affect
the stability of mtDNA.
The atp6-L183P mutant grew nearly identically to the wild type on
a non-fermentable substrate (glycerol) both at 28 °C, the optimal
temperature for growing yeast (Fig. 1), and at 36 °C (not shown). This
did not imply that the atp6-L183P mutation had no deleterious effects
on the ATP synthase. Indeed, usually, mutations of the ATP synthase
need to decrease the rate of ATP synthesis by more than 80% to affect
the growth of yeast on respiratory substrates [38], which was
observed with the atp6-L183R mutant where this activity was below
10% of the wild type level [14] (see also Fig. 1).
3.2. Consequences of the atp6-L183P mutation on several activities
related to respiration and oxidative phosphorylation
a) Oxygen consumption—Mitochondria isolated from the atp6-
L183P mutant and the corresponding wild type strain (MR6) were
assayed for oxygen consumption. With NADH as an electron donor,
the basal (state 4) oxygen consumption rate was about the same for
the two strains (Table 2). However, in the presence of an excess of ADP
(state 3), the oxygen consumption rate was much less stimulated in
the mutant than in the wild type, 1.4-fold and 2.2-fold, respectively. In
the presence of the membrane potential uncoupler CCCP, where
respiration is maximal, the oxygen consumption rate was still
substantially lower in the atp6-L183P mutant than in the wild type.
However, the CCCP-induced increase in respiration relative to state 3
was about the same for the mutant and thewild type, 1.9-fold and 1.8-
fold respectively, indicating that the atp6-L183P mutation did not
modify the passive permeability for protons of inner mitochondrial
membrane.
The atp6-L183P mutant also showed a signiﬁcant respiratory
deﬁcit when electrons were delivered at the level of complex II from
succinate (not shown), or complex IV from ascorbate/TMPD,Fig. 1. Growth of yeast atp6 mutants. Freshly grown cells of wild type (MR6), Δatp6 (MR10
(YPGA) and rich glycerol (N3) media. The plates were incubated at 28 °C and photographerespectively (Table 2). Several lines of evidence indicated that the
50% drop in complex IV activity in the mutant was due to a lesser
protein content of this complex. First, in cytochrome spectra recorded
fromwhole cells chemically reduced with dithionite the cytochromes
aa3 of complex IV were about two times less abundant in the mutant
than in the wild type. The cytochromes c1 and b of complex III were in
normal amounts indicating that the atp6-L183P mutation did not
affect the content of this complex (Fig. 2). This was corroborated by
SDS-PAGE analyses of mitochondrial proteins showing the level of the
Cox2p subunit of complex IV largely decreased in the mutant while
the amount of the cytochrome b subunit of complex III was almost
normal (Fig. 3C).
We further analyzed the impact of the atp6-L183P mutation on the
complexes III and IV by BN-PAGE. In the conditions used, these
complexes are mainly resolved as two supercomplexes consisting of
one complex III dimer combined with either one (III2IV1) or two
(III2IV2) complexes IV, and a small amount of free complex III [39]. In
the wild type, III2IV2 was much more abundant than III2IV1, which is
clearly apparent in the Western blots made with antibodies against
Cox2p (Fig. 3B). With the antibodies against cytochrome b, it looks
that III2IV1 was more abundant than III2IV2 but this is an artifact
because these antibodies have a reduced access to complex III when it
is associated with complex IV.
From the Western blots made with antibodies against Cox2p the
III2IV2 complex was signiﬁcantly less abundant in the atp6-L183P
mutant than in the wild type, whereas the amount of III2IV1 was
unchanged (Fig. 3B). From the blots made with antibodies against
cytochrome b, it became also clear that the mutant contained more
free complex III compared to the wild type. This is due to the
pronounced effect of atp6-L183P on complex IV, which reduces the
amount of complex III that is incorporated into supercomplexes.
We previously reported that the amount of complex IV was also
selectively decreased in a yeast strain lacking the entire ATP6 gene
(Δatp6) by 95% and in a yeast model of the NARP/MILS T8993G
mutation, atp6-L183R, by 80% [14,25]. The poor expression of
complex IV in these two strains correlated with a decrease in the
synthesis of the mitochondrially encoded Cox1p subunit of this
complex. A clear diminution in Cox1p synthesis was also found in the
atp6-L183P mutant, by in vivo radioactive labeling of mitochondrial
translation products (Fig. 4). As revealed by real-time PCR (see
Experimental procedures), there was no signiﬁcant difference in the
level of COX1 mRNA between the atp6-L183P mutant and wild type,
indicating that a less efﬁcient translation was responsible for the
deﬁcit in newly synthesized Cox1p in the mutant, as was previously
also observed in Δatp6 [25] and atp6-L183R [14] yeast strains. We do
not know the nature of the extra radioactive bands in the atp6-L183P
mutant lane, one between Cox2p and Cox3p and two below Atp6p.), atp6-L183R (MR14) and atp6-L183P (RKY20) strains were spotted onto rich glucose
d after the indicated number of days.
Table 2
Inﬂuence of the atp6-L183P mutation on yeast mitochondrial respiration, ATP hydrolytic, and ATP synthesis activities.
Strain Respiration rates ATPase activity ATP synthesis rate
nmol O min−1 mg−1 nmol Pi min−1 mg−1 nmol Pi min−1 mg−1
NADH NADH+ADP NADH+CCCP Asc/TMPD+CCCP −oligo +oligo −oligo +oligo
MR6 279±17 613±12 1081±107 2013±290 4.474±0.222 0.665±0.108 637±18 15±8
RKY20 257±39 357±20 684±33 1013±68 4.725±0.595 2.838±0.045 317±21 58±23
Mitochondria were isolated fromwild type (MR6) and atp6-L183P (RKY20) cells grown for 5–6 generations in YPGALAmedium (rich galactose) at 28 °C. Additions were 0.15 mg/ml
proteins, 4 mMNADH, 150 μM ADP, 12.5 mM ascorbate (Asc), 1.4 mMN,N,N,N,-tetramethyl-p-phenylenediamine (TMPD), 4 μM CCCP, 3 μg/ml oligomycin (+O). The MR6 and RKY20
cultures contained 2% and 3% ρ−/ρ0 cells, respectively. The values reported are averages of triplicate assays±standard deviation. Respiration and ATP synthesis activities were
measured on freshly isolated osmotically-protected mitochondria buffered at pH 6.8. For the ATPase assays, mitochondria kept at −80 °C were thawed and the reaction was
performed in the absence of osmotic protection and at pH 8.4.
Fig. 2. Cytochrome spectral analysis. The tracings are optical spectra of mitochondrial
cytochromes chemically reducedwith dithionite recorded at liquid nitrogen temperature
fromwhole cells of wild type (MR6) and atp6-L183P strains. The positions of theα band
absorption maxima of cytochrome c (c), cytochrome c1 (c1), cytochrome b (b), and
cytochromes aa3 (aa3) are indicated.
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synthesized Cox1p but they are present in such low amounts that
proteolytic degradation alone is certainly not responsible alone for
the deﬁcit in radioactive Cox1p polypeptides. Despite a diminished
steady state accumulation, Cox2p synthesis was normal. This is
because unassembled Cox2p proteins are quickly eliminated by the
Yme1p protease [40].
b) Mitochondrial ATP synthesis/hydrolysis—The consequences of
the atp6-L183P mutationwere analyzed further by measuring the rate
of mitochondrial ATP synthesis, at state 3 with NADH as a respiratory
substrate. This activity was found to be reduced in the mutant by
about 40–50% compared with the wild type. As the rate of oxygen
consumption, measured under exactly the same conditions, was
reduced in a similar proportion (see above), it appeared that the
efﬁciency of oxidative phosphorylation, i.e. the number of ATP
molecules formed per electron transferred to oxygen, was mostly
unaffected by the atp6-L183P mutation.
We next measured the rate of ATP hydrolysis by non-osmotically
protected mitochondria buffered at pH 8.4, i.e. in conditions where
the hydrolysis of ATP by the F1 cannot sustain a mitochondrial
membrane potential. The mitochondrial ATPase activity of atp6-L183P
mutant was about the same as that of the wild type. However, it was
rather poorly inhibited by oligomycin, by 40% versus 85% for wild type
(Table 2).
c) ATP-driven translocation of protons across the inner mitochondrial
membrane—The inﬂuence of the atp6-L183P mutation on the proton
pumping capacity of the F1F0 complex was evaluated using Rhoda-
mine 123. This is a ﬂuorescent cationic dye that can be used tomonitor
changes in the mitochondrial membrane potential (ΔΨ) on intact
(osmotically protected) mitochondria [30]. Increasing ΔΨ is followed
by the uptake of the dye inside the matrix space and concomitant
ﬂuorescence quenching. Prior to testing for ATP-driven proton
translocation the mitochondria were ﬁrst energized with ethanol to
remove the natural inhibitory peptide (IF1) of the F1-ATPase (Fig. 5).
The mitochondrial membrane potential was then collapsed with KCN,
and less than 1 min later, thus well before rebinding of IF1 [41], ATP
was added. The external ATP is counter-exchanged against ADP from
the matrix by the ADP/ATP translocase. No ΔΨ is required, the
presence of ADP in the matrix sufﬁces to trigger the import of ATP
into the mitochondria. The ATP can then be hydrolyzed by the F1
coupled to the transport of protons out of the matrix through the F0.
As can be seen in Fig. 5, the ATP addition promoted both in the
mutant and wild type mitochondria a large and stable ﬂuorescence
quenching of the dye that was reversed upon inhibition of the F0 with
oligomycin (Fig. 5).
3.3. Assembly/stability of the ATP synthase in the atp6-L183P mutant
We next examined the inﬂuence of the atp6-L183P mutation on
the ATP synthase assembly/stability using the BN-PAGE technique.
After their electrophoretic separation, the digitonin-extracted mito-
chondrial proteins were transferred onto a nitrocellulose membrane
and successively hybridized with antibodies against four subunitswhich are representative of the different ATP synthase domains, the
proton channel (Atp6p or Atp9p), the peripheral stalk (Atp7p or
OSCP) and the F1 (Atp1p or subunit α). Between two hybridizations,
the membrane was stripped to completely remove the previously
hybridized antibodies. The antibodies against Atp6p and Atp7p gave
for both the mutant and wild type only two immunological signals
corresponding to fully assembled dimeric or monomeric F1F0
complexes (Fig. 3A). The antibodies against Atp9p and Atp1p revealed
for the mutant a number of additional signals that were virtually
absent in the wild type: the Atp9p-ring, the F1, unassembled α
subunits, and α/β dimers.
Interestingly, exactly the same ATP synthase subcomplexes are
detected in a Δatp6 yeast [25] and in a strain where the incorporation
of Atp6p within the ATP synthase is compromised by the deletion of
the N-terminal peptide of Atp6p [22] (Fig. 3A). Pulse-chase analyses of
mitochondrial translation products revealed that Atp6p was efﬁ-
ciently synthesized in the atp6-L183P mutant, apparently even more
so than in thewild type (Fig. 4) and the newly synthesized atp6-L183P
Fig. 3. SDS- and BN-PAGE analyses of mitochondrial proteins. Panel A, BN-PAGE analyses of the ATP synthase. Mitochondria from wild type (MR6), Δatp6 (MR10), atp6-L183R
(MR14) and atp6-L183P (RKY20) strains were solubilized with 2 g of digitonin per gram of protein. The digitonin-extracted proteins (50 μg) were separated by BN-PAGE,
transferred to a nitrocellulose membrane, and successively hybridized with antibodies against Atp6p, Atp9p, Atp7p (OSCP subunit) and Atp1p (α-F1 subunit). Between two
hybridizations, the membrane was washed to completely remove the previously hybridized antibodies. Panel B, BN-PAGE analyses of complexes III and IV. Mitochondria fromwild
type (MR6) and atp6-L183P (RKY20) strains were solubilized with 10 g of digitonin per gram of protein. The digitonin-extracted proteins (50 μg) were separated by BN/PAGE,
transferred to a nitrocellulose membrane, and hybridized with antibodies against the cytochrome b subunit of complex III or the Cox2p subunit of complex IV. Panel C, SDS-PAGE
analyses of total mitochondrial proteins. Mitochondrial proteins (10 μg) were separated by SDS-PAGE, transferred to a nitrocellulose membrane and probed with antibodies against
the indicated proteins. Data are representative of at least three experiments.
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type (not shown). There was thus clearly no Atp6p synthesis deﬁcit in
the atp6-L183P mutant indicating that the ATP synthase assembly
defects in this mutant resulted from a less efﬁcient incorporation of
Atp6p within the ATP synthase (see Discussion). The 30–40% decrease
in the steady-state level of Atp6p in the atp6-L183P mutant (Fig. 3C)
may be due to elimination from the cells of the unassembled Atp6p
proteins. The Atp9p subunit, which is known to be insensitive to most
defects in the assembly of the other subunits of the ATP synthase [42],
showed a normal accumulation in the atp6-L183P mutant (Fig. 3C).
4. Discussion
The present study describes the construction and properties of a
yeast strain bearing an equivalent of the T8993C mutation of human
mtDNA found in NARP/MILS patients. This mutation leads to the
replacement by proline of a highly conserved leucine residue (156 in
humans, 183 in yeast) of the Atp6p (or a) subunit of the ATP synthase.This transmembrane protein is presumed to contain most of the
residues involved in F0-mediated proton transport [5]. Proton move-
ments through the F0 induce the rotation of a transmembrane ring of
Atp9p (or c) subunits that contacts Atp6p. The leucine residue
modiﬁed by T8993C is within an α-helical trans-membrane segment
just three residues away from the essential arginine residue of Atp6p
(159 in humans, 186 in yeast) that is known to face the Atp9p-ring
near the middle of the membrane [4]. From such an arrangement it
can be inferred that converting this leucine into a residue that cannot
be easily accommodated withinα-helices could affect the interactions
of Atp6p with Atp9p and/or the functioning of the Atp9p-ring/Atp6p
system. However, despite unequivocal genetic evidence for the
propensity of this mutation to induce severe neurological disorders
in humans, there is no clear evidence for such ATP synthase defects,
especially in studies using cultured T8993C cells (cybrids, ﬁbroblasts).
Only a minor, if any, ATP production, as well as no visible defect in the
assembly of the ATP synthase, were detected in these cells [4,8,10].
However, in a recent study of fresh muscle biopsies from T8993C
Fig. 4. Mitochondrial protein synthesis. Proteins encoded by mtDNA were labeled in
whole cells from wild type (MR6) and atp6-L183P (RKY20) strains with [35S]-
(methionine+cysteine) for 20min in the presence of cycloheximide to inhibit cytosolic
protein synthesis. After the labeling reaction, the mitochondrial membranes were
extracted and loaded on an SDS-PAGE gel (100,000 cpm per lane). After electrophoresis,
the gel was dried and the labeled proteins visualized with a PhosphorImager.
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50% and partial defects in the assembly of the ATP synthase were
found [11]. Whether the consequences of T8993C on the human ATP
synthase are partially ‘masked’ in cultured cells or whether they are
‘exacerbated’ when patients' tissues are directly used to analyze them
remains an open question.
In view of these important but controversial results, we decided to
determine the consequences of the leucine to proline pathogenic
change in yeast, an organismwhere the ATP synthase is highly similar
to the human enzyme [13,42]. Yeast cells homoplasmic for the atp6-Fig. 5. ATP driven translocation of protons across the inner mitochondrial membrane. The p
evaluated by ﬂuorescence quenching of rhodamine 123 using intact mitochondria isolated
rhodamine 123, 0.15 mg/ml mitochondrial proteins (Mito), 10 μl of ethanol (EtOH), 6 μg/ml o
representative of at least three experiments.L183P mutation show a 40–50% decrease in the rate of mitochondrial
ATP synthesis. The ATP production deﬁcit correlates with alterations
of the ATP synthase. First, the mutant mitochondrial ATPase activity,
although as high as that of the wild type, was poorly inhibited by
oligomycin, by only 40% versus 85% for the wild type. Second, BN-
analyses of atp6-L183P mitochondrial extracts revealed, in addition to
fully assembled F1F0 complexes, the presence of several ATP synthase
subcomplexes (the Atp9p-ring, the F1, and unassembled α-F1
subunits) not detected in the wild type. Interestingly, exactly the
same subcomplexes were found in a yeast strain lacking the entire
ATP6 gene (Δatp6) and in a strain where incorporation of Atp6p
within the ATP synthase is compromised by the deletion of the N-
terminal leader peptide of Atp6p, respectively [22,25]. We have
provided direct biochemical evidence that the ATP synthase sub-
complexes detected in Δatp6 yeast arise from dissociation of large
assemblies lacking Atp6p [25]. These assemblies are very fragile and
easily dissociate upon detergent-extraction and/or during electro-
phoresis. It can be inferred that Atp6p may be inserted in a late step of
the ATP synthase assembly pathway and that most if not all of the
other complex subunits do not require the presence of Atp6p to
associate to each other. On the other hand, it has been found that
Atp6p is present in only very low levels in most yeast ATP synthase
assembly defective mutants, even in those mutants showing a good
synthesis of Atp6p [42]. Altogether these observations indicate that to
be inserted Atp6p requires a preformed structure containing most of
the other ATP synthase subunits and that unassembled Atp6p proteins
are ﬁnally eliminated from the cells.
Thus, a logical conclusion is that the ATP synthase in atp6-L183P
cells can be divided into two different populations, one of which is
correctly assembled and active, and the other that is less stable or not
fully assembled and capable to only hydrolyze ATP, the latter being
insensitive to oligomycin. As Atp6p was efﬁciently synthesized in the
atp6-L183P mutant, even more than in the wild type, one can ascribe
the presence of incomplete ATP synthase complexes in this mutant to a
decreased stability or a less efﬁcient assembly of Atp6p rather than to a
lack of production of this subunit. One possibility is that the atp6-L183P
mutation may delay the folding/insertion of Atp6p by weakening the
interactions with chaperone(s) (Atp10p [43], Atp23p [44]) speciﬁcally
actingonAtp6p; alternatively themutationmay result in a less efﬁcient
interaction of Atp6p with the Atp9p-ring. The 30–40% decrease in the
steady-state concentration of Atp6p in the atp6-L183P mutant may
reasonably be accounted for by elimination of the unassembled Atp6p
proteins from the cells [42–45].roton pumping activity of the F1F0 complex driven by F1-catalyzed ATP hydrolysis was
from wild type (MR6) and atp6-L183P (RKY20) strains. The additions were 0.5 μg/ml
ligomycin (oligo), 0.2 mM potassium cyanide (KCN), 1 mM ATP, and 3 μM CCCP. Data are
823R. Kucharczyk et al. / Biochimica et Biophysica Acta 1793 (2009) 817–824Despite a 30–40% lack in fully assembled ATP synthase complexes,
atp6-L183P mitochondria showed a normal ATP-driven proton-
translocation activity. In this regard, it is to be noted the F1F0 complex
hydrolyzes ATP very slowly against a proton gradient, whereas in the
ATPase assays, which are performed on non-osmotically protected
mitochondria, the ATPase is fully “relaxed” due to the absence of any
membrane potential. Clearly, there are more than enough fully
assembled and functional F1F0 complexes in atp6-L183P cells to
sustain a good ATP-driven proton translocation. The full sensitivity to
oligomycin of the proton-translocation activity of mutant cells is not
inconsistent with the poor sensitivity of the ATPase activity in these
cells (40% versus 85% in wild type cells) to this drug. Indeed, only the
complete F1F0 complexes present in atp6-L183P cells can pump
protons and these complexes are apparently normally inhibited by
oligomycin, whereas in the ATPase assays only the partial assemblies
lacking Atp6p can hydrolyze ATP in the presence of oligomycin.
Intriguingly, the yeast atp6-L183P mutant showed reduced
mitochondrial respiration compared to the wild type, apparently
because of a 50% reduction of complex IV content. A strong and
selective decrease in the amount of complex IV has also been found in
Δatp6 yeast and in a yeast model of the NARP/MILS T8993G mutation
(atp6-L183R), of 95% and 80%, respectively [14,25]. In the atp6-L183R
mutant, the ATP synthase is correctly assembled but works very
slowly because of a blockage in the proton channel [14]. Thus it seems
that it is the activity of the ATP synthase that correlates with the
amount of complex IV. Consistent with this, a decrease in complex IV
content was also observed when wild type yeast was grown in the
presence of oligomycin (E. Tetaud, R. Kucharczyk and J.P. di Rago,
unpublished).
Interestingly, the mitochondrially-encoded Cox1p subunit of
complex IV is very poorly synthesized in Δatp6 yeast [25], which
may account for the major deﬁcit in complex IV in this strain. In the
atp6-L183R [14] and atp6-L183P yeast strains investigated in this
study, Cox1p synthesis is also reduced although to a lesser extent than
in Δatp6 yeast. These ﬁndings are especially interesting in view of
previous studies showing that Cox1p synthesis is a key regulatory
target for the control of complex IV abundance in yeast [46,47].
Indeed, with a few exceptions, Cox1p translation was selectively
slowed down in yeast coxmutants in which newly synthesized Cox1p
polypeptides cannot assemble due to genetic lesions in assembly
factors or subunits of complex IV [46]. From these observations it has
been proposed that the synthesis of Cox1p is coupled to its entry into
the COX assembly pathway [46]. It will be interesting to determine
whether this regulatory loop is involved in the apparent regulation of
complex IV content by the ATP synthase in yeast mitochondria.
Why complex IV expression is controlled by the ATP synthase in
yeast is certainly an interesting question. As we already had suggested
[14,25], this control can perhaps serve in adjusting the rate of electron
ﬂow to the activity of complex V or to a parameter that depends on
this activity, like the mitochondrial membrane potential which tends
to increase when F0-mediated proton ﬂow decreases. Such a
regulation may be of crucial importance in yeast cells that have to
cope with important ﬂuctuations in their natural habitat. There is no
evidence for the existence of a control of complex IV abundance by the
ATP synthase in human cells. In most reported cases primary
deﬁciencies in human ATP synthase are not accompanied by any
signiﬁcant decrease in the contents of the different respiratory
enzymes [48]. There are some indications however that ATP synthase
deﬁciencies in human cells may result in oxidative damage of the
respiratory complexes through an increased ROS production [49,50].
We failed to detect any signiﬁcant increase in ROS production in yeast
ATP synthase deﬁcient mutants or in wild type cells inhibited with
oligomycin (N. Carette, J.-P. di Rago, and S. Manon, unpublished).
We believe that the pathogenic mutations of humans introduced
into yeast ATP6 presented here will help shine some light on the
overall consequences for the activity and function of the ATP synthase.We have shown previously that the T8993Gmutation has in yeast, like
in human, a very severe effect on the ATP synthesis activity due to a
local disruption of the enzyme proton channel [10,14]. As in humans
[4], the present study reveals that the T8993C mutation has much less
deleterious consequences than T8993G in yeast. As discussed above,
the ATP production deﬁcit in T8993C yeast (atp6-L183P) seems to be
largely caused by defects in the incorporation of Atp6p within the ATP
synthase. Whether the leucine to proline pathogenic change provokes
similar defects in humans is an open question. In a recent study it was
concluded that the ATP synthase was correctly assembled in
homoplasmic T8993C cultured cells [10]. However, assembly defects
and ATP production deﬁcits very similar to the ones occurring in
T8993C yeast where found in fresh muscle biopsies of patients
containing a high load (N95%) of T8993C [11]. Little is known about
the assembly of Atp6p in humans. It is possible that human Atp6p is
inserted in a late step of the ATP synthase assembly pathway like in
yeast, concerning the conservation of speciﬁc chaperones of the ATP
synthase in humans, among those Atp23p, a protein which assists the
folding/insertion of Atp6p in yeast [44].
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